logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Luz-Maria Guzman

USPTO Granted Patents = 12 

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:

goldMedal11 out of 850 
 
Millennium Pharmaceuticals Limited
 patents
silverMedal1 out of 36 
 
Millenium Pharmaceuticals, Inc.
 patents

Years Active: 2002-2008

Loading Chart...
12 patents (USPTO):Explore Patents
1. 7329508 - Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides (2008-02-12),
2. 7074585 - Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides (2006-07-11),
3. 6995134 - Use of yneS, essential bacterial genes and polypeptides (2006-02-07),
4. 6815177 - Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides (2004-11-09),
5. 6749858 - Essential bacterial genes and their use (2004-06-15),
6. 6664074 - Use of yacM and yqeJ, essential bacterial genes and polypeptides and their use (2003-12-16),
7. 6638729 - Use of YLQF, YQEG, YYBQ, and YSXC, essential bacterial genes and polypeptides (2003-10-28),
8. 6627747 - Essential bacterial genes and their use (2003-09-30),
9. 6515119 - Use of S-ydcB and B-ydcB, essential bacterial genes (2003-02-04),
10. 6472377 - Use of YNES, essential bacterial genes and polypeptides (2002-10-29),
11. 6437108 - Essential bacterial genes and their use (2002-08-20),
12. 6372448 - Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides (2002-04-16),

Title: Luz-Maria Guzman: Innovator in Digestive Health Treatments

Introduction: Luz-Maria Guzman is an inventor based in Watertown, MA (US). He is focused on developing innovative methods for treating digestive disorders. His work primarily revolves around the use of ACE2 inhibitors in various therapeutic applications.

Latest Patent Applications: Guzman's latest patent applications include a method for treating acute or chronic pancreatitis. This method involves administering a therapeutically effective amount of an ACE2 inhibitor to the subject. Another application focuses on managing or treating inflammatory, erosive, dyspeptic, or reflux disorders of the proximal digestive tract. This method also utilizes an ACE2 inhibitor for effective treatment. Additionally, he has proposed a therapeutic combination that includes an NSAID and a gastroprotective agent comprising an ACE2 inhibitor. This combination aims to protect the mucosal surfaces of the proximal digestive tract from erosion or ulceration induced by NSAIDs.

Conclusion: Luz-Maria Guzman is making significant strides in the field of digestive health through his innovative approaches. His latest patent applications highlight his commitment to improving treatment options for patients suffering from digestive disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…